PURE Bioscience, Inc. (NASDAQ: PURE),
the creator of the patented silver dihydrogen citrate (SDC)
antimicrobial, today announced the closing of an underwritten public
offering of 3,784,000 shares of its common stock at an offering price of
$1.10 per share.
In addition, the Underwriter has exercised the
over-allotment option, and purchased an additional 557,615 shares of
common stock to cover over-allotments. The gross proceeds to PURE from
the offering, including the exercise of the over-allotment option, were
approximately $4,775,777, before deducting the underwriting discount and
other offering expenses payable by PURE.
Aegis Capital Corp. acted as the sole book-running manager for the
offering.